ArticleReviews in cardiovascular medicine2025
Updated Trends in Valvular Heart Disease-Related Heart Failure in G20-the Group of Twenty Countries: Insights From the Global Burden of Disease Study 2021.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Periodontal Disease Burden in China and G20 Nations: Insights From the Global Burden of Disease 2023 Study.International dental journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Valvular heart disease (VHD), including both non-rheumatic valvular heart disease (NRVHD) and rheumatic valvular heart disease (RVHD), is a major global health concern. Moreover, the progression of VHD to heart failure (HF) poses substantial clinical and public health challenges. In light of the global population aging, alongside increasing cardiovascular risk factors, and the additional strain imposed by the COVID-19 pandemic, a timely reassessment of the VHD-related HF burden is urgently needed. Using the most recent data from the Global Burden of Disease (GBD) Study 2021, this study aimed to evaluate the distribution of VHD-related HF burden in 2021, examining the long-term trends from 1990 to 2021, and short-term changes between 2019 and 2021, to provide updated insights to inform future prevention and management strategies. Methods: Using GBD 2021 data, we analyzed the distribution of VHD-related HF burden in age-standardized prevalence rates across the Group of Twenty (G20) countries. Results: The highest NRVHD-related HF burden in 2021 was observed in the United States (US), Italy, and Russia, while the highest RVHD-related HF burden was noted in India, France, and China. Over the past 30 years (1990-2021), the NRVHD-related HF burden decreased in developed countries (e.g., the US, Canada, Japan) but increased in emerging economies (e.g., India, Brazil, South Africa), with significant increases also observed in Argentina, Mexico, Brazil, among other countries. Notably, nearly all G20 countries exhibited a downward trend in RVHD-related HF burden, with Germany and Australia being the exceptions. During the COVID-19 pandemic (2019-2021), the NRVHD-related HF burden declined in most G20 nations, except for South Africa, India, and a few others, while the RVHD-related HF burden increased slightly in countries such as Mexico, Russia, and Indonesia. Conclusions: Trends in NRVHD- and RVHD-related HF burden across G20 countries exhibited notable variations, and these became more pronounced under the impact of the COVID-19 pandemic. These findings underscore the importance of developing long-term strategies to enhance the resilience of healthcare systems, improve chronic disease management, and optimize resource allocation to promote cardiovascular health and preparedness for public health challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.